G6PD activator AG1_product_DataBase

Bioactivity	G6PD activator AG1 is a potent and selective glucose-6-phosphate dehydrogenase (G6PD) activator with an EC50 of 3 µΜ[1]. G6PD activator AG1 reduces hemolysis of human erythrocytes[2].
Target	IC50: 3 µΜ (G6PD)
Invitro	AG1 (50, 100, 250, 500, 750, 1000 nM) of 1 μM increases the viability by 20% and the proteolytic stability of Canton G6PD in SH-SY5Y cells. AG1 has no effect when G6PD was knocked down by siRNA, supporting the specificity of AG1 toward G6PD[2]. AG1 (1-5 μΜ; pre-incubated overnight) reduces the extent of hemolysis with 5 μΜ in human erythrocytes suspension (5%) exposed to either 1 mM chloroquine (CQ; 4 hours) or diamide (a GSH oxidant; 4 hours). AG1 increases GSH levels and reduced ROS levels together with increased G6PD activity under these drug-induced oxidative stress[2]. AG1 has no effect on the dimerization or activity of several other NAD- or NADP+-dependent dimeric or tetrameric enzymes, including 6-phosphogluconate dehydrogenase (6PGD), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), aldehyde dehydrogenase 2 (ALDH2), and aldehyde dehydrogenase 3A1 (ALDH3A1)[2].
Name	G6PD activator AG1
CAS	421581-52-4
Formula	C24H30N4S2
Molar Mass	438.65
Appearance	Oil
Transport	Room temperature in continental US; may vary elsewhere.
Storage	4°C, protect from light *该产品在溶液状态不稳定，建议您现用现配，即刻使用。
Reference	[1]. https://patents.google.com/patent/WO2019023264A1/en?oq=WO2019023264A1 [2]. Kaitlyn Ryan, et al. Current investigations on clinical pharmacology and therapeutics of Glucose-6-phosphate dehydrogenase deficiency. Pharmacol Ther. 2020 Dec 14;222:107788.

PeptideDB

G6PD activator AG1

CAS: 421581-52-4 F: C24H30N4S2 W: 438.65